Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Wednesday, November 14, 2018 · 468,232,807 Articles · 3+ Million Readers

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pinduoduo, CV Sciences, and Ampio and Encourages Investors to Contact the Firm

NEW YORK, Oct. 21, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Pinduoduo Inc., CV Sciences, Inc., and Ampio Pharmaceuticals, Inc.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.  Additional information about each case can be found at the link provided.

Pinduoduo Inc. (NASDAQ: PDD)

Class Period: July 26, 2018 – July 31, 2018

Lead Plaintiff Deadline: October 22, 2018

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  In the Registration Statement and Prospectus issued in connection with Pinduoduo’s IPO, defendants made materially false and misleading statements regarding the company’s business, operational, and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) Pinduoduo’s controls were ineffective to prevent third-party vendors from selling counterfeit goods on the company’s online platform; (2) consequently, Pinduoduo’s revenues and the number of active merchants using its platform were traceable in part to unlawful conduct and thus unsustainable; and (3) as a result, Pinduoduo’s public statements were materially false and misleading at all relevant times.

To learn more about the Pinduoduo class action go to: http://bespc.com/pdd/

CV Sciences, Inc. (Other OTC: CVSI)

Class Period: June 19, 2017 - August 20, 2018

Lead Plaintiff Deadline: October 23, 2018

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, defendants failed to disclose that the company’s Patent #15/426,617: (1) received a non-final rejection from the USPTO on April 27, 2017; (2) a final rejection from the USPTO on December 14, 2017; and (3) as a result of the foregoing, defendants’ statements about CV Sciences’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. 

To learn more about the CV Sciences class action go to:  https://bespc.com/cvsi/.

Ampio Pharmaceuticals, Inc. (NYSE: AMPE)

Class Period: December 14, 2017 – August 17, 2018

Lead Plaintiff Deadline: October 24, 2018

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, defendants’ public statements were materially false and misleading at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages. 

To learn more about the Ampio class action go to:  https://bespc.com/ampio/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.

Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com 
www.bespc.com

/EIN News/ --

BES_Mark.jpg

Powered by EIN News
Distribution channels: Consumer Goods, Law
Submit your press release